By Sherri Oslick —

About
Court Report:  Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.

Sepracor Inc. et al. v. Synthon Pharmaceuticals, Inc. et al.
5:08-cv-00179; filed April 11, 2008 in the Eastern District of North Carolina

Sepracor Inc. et al. v. Synthon Pharmaceuticals, Inc. et al.
1:08-cv-00207; filed April 10, 2008 in the District Court of Delaware

Infringement of U.S. Patent No. 5,698,558 ("Methods for Treating Allergic Disorders Using Optically Pure (-)Cetirizine," issued December 16, 1997), licensed to UCB, following a paragraph IV certification as part of Synthon’s filing of an ANDA to manufacture a generic version of UCB’s XYZAL® (levocetirizine dihydrochloride, used to treat seasonal and perennial allergic rhinitis).  The complaints in these cases are substantially identical.  View the Delaware complaint here.